7th Inflammasome Therapeutics Summit

Now in its 7th year, the Inflammasome Therapeutics Summit is the only industry forum focused exclusively on inflammasome-targeted drug development. Over three action-packed days, we will unpack high-impact case studies from the front lines – covering emerging upstream and downstream targets, mechanisms beyond canonical pathways, and how these insights are unlocking new disease areas from neuroinflammation and atopic dermatitis to obesity and fibrotic conditions.

The 7th Inflammasome Therapeutics Summit is your go-to forum for drug developers, translational scientists, and immunology innovators striving to push inflammasome-targeted therapies from concept to clinic. Join 70+ leaders across pharma, biotech, and academia as they converge to decode the latest clinical readouts and explore novel therapeutic avenues beyond NLRP3.

Get ready for in-depth sessions on optimizing translational models, identifying next-gen biomarkers, and mapping inflammasome signalling across diverse indications. If you are serious about leading the charge in inflammasome drug development, this is where the future takes shape.

Companies attending include:

Novartis, Inflammasome Therapeutics, Pfizer, Oddity, Monte Rosa Therapeutics, Harvard Medical School, Neurocrine Biosciences

And many more!

Join your peers to hear directly from those driving programs forward, tackle the most pressing translational challenges, and help chart the future of inflammasome therapeutics.

Ready to catalyze the next wave of inflammasome therapies? Find out more about our expert speakers and their sessions by downloading our full event guide here: https://ter.li/9w3hvb